A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

NCT02491463 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Synctial Virus Infections

Interventions

BIOLOGICAL: GSK3389245A_LD GROUP
BIOLOGICAL: GSK3389245A_HD GROUP
BIOLOGICAL: Bexsero
DRUG: Placebo

Sponsor

GlaxoSmithKline